Treatment of experimental chronic pulmonary mycoplasmosis

• Published in: International journal of antimicrobial agents Vol. 28; no. 3; pp. 253 - 258
• Main Authors: Fonseca-Aten, Monica, Rios, Ana Maria, Mejias, Asuncion, Chavez-Bueno, Susana, Katz, Kathy, Gomez, Ana Maria, Ramilo, Octavio, McCracken, George H., Hardy, R. Doug
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01.09.2006; Amsterdam Elsevier; New York, NY
• Subjects: Animals; Anti-Bacterial Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Asthma; Biological and medical sciences; Chronic Disease; Chronic infection; Chronic obstructive pulmonary disease, asthma; Disease Models, Animal; Female; Ketolides - therapeutic use; Medical sciences; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Mycoplasma pneumoniae - drug effects; Pharmacology. Drug treatments; Plethysmography; Pneumology; Pneumonia; Pneumonia, Mycoplasma - drug therapy; Pneumonia, Mycoplasma - pathology; Pneumonia, Mycoplasma - physiopathology; Reactive airway disease; Telithromycin; Mycoplasma pneumoniae; Chronic infection; Telithromycin; Pneumonia; Reactive airway disease; Asthma; Mollicutes; Respiratory tract; Mycoplasmatales; Bacteria; Bronchus disease; Obstructive pulmonary disease; Protein synthesis inhibitor; Lung disease; Respiratory disease; Macrolide; Mycoplasmataceae; Infection; Antibiotic; Chronic; Treatment; Bacteriosis; Antibacterial agent; Ketolide; Mycoplasmal infection
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2006.04.008

Mycoplasma pneumoniae infection has been associated with chronic lung disease. Treatment of chronic pulmonary mycoplasmosis has not been well investigated. BALB/c mice were intranasally inoculated once with M. pneumoniae or with sterile media (uninfected controls). Infected mice were treated with telithromycin or placebo daily for 10 days in the chronic phase of disease (18 months after inoculation). Mice ( n = 43) were evaluated before therapy and 1 day after completion of telithromycin. Treatment of infected mice with telithromycin at 18 months after infection significantly reduced chronic pulmonary histological inflammation compared with infected mice given placebo; however, this treatment did not improve airway obstruction or airway hyperresponsiveness. Therapy longer than 10 days may be necessary to improve pulmonary function.